Late-Breaking Phase 3 Data at AAD 2023 Show Oral Investigational Medicine Deuruxolitinib Significantly Improved Scalp Hair Regrowth in Alopecia Areata ...
Osteoarthritis Candidate MM-II Showed Durable Pain Relief in Global Phase 2b Study Source link
Sun Pharma launches CEQUA, a novel therapy for Dry Eye Disease in India Source link
Sun Pharma to announce fourth quarter results on May 26, 2023 Source link
Q4 FY23 Financial Press Release Source link
Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, ...
Sun Pharma Announces China NMPA Approval For ILUMETRI (Tildrakizumab Injection) For Treatment Of Adults with Moderate-To-Severe Plaque Psoriasis Source link
Sun Pharma Announces Health Canada Approval of PRWINLEVI® (clascoterone cream 1%) for Topical Treatment of Acne Source link
ADA GL0034 Data Release Source link
Sun Pharma launches nationwide initiative, #SecondBirthDate on National Doctor’s Day Source link
Sun Pharma to announce first quarter results on August 03, 2023 Source link
Sun Pharma and Pharmazz Inc. enter into licensing agreement for introducing Tyvalzi™ (Sovateltide) in India Source link
Sun Pharma Canada Launches PR WINLEVI® (clascoterone cream 1% w/w), a Novel Topical Treatment for Acne Source link
Sun Pharma Announces US FDA Filing Acceptance of New Drug Application For Deuruxolitinib Source link
CEQUA® (cyclosporine ophthalmic solution) 0.09% Phase 4 Data Showed Sustained Improvement in Dry Eye Disease Signs and Symptoms in Patients ...
Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival ...
Sun Pharma to announce second quarter results on November 01, 2023 Source link
Sun Pharma and Zydus sign licensing agreement for co-marketing of Desidustat in India Source link
